The Simoa Human Neurology 4-Plex A assay (N4PA) measures four important neurology biomarkers in both cerebrospinal fluid (CSF) and blood. The four targets are neurofilament light (NF-L) total tau, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1). All four biomarkers have been studied as indicators of traumatic brain injury (TBI) severity. Recent reports indicate serum NF-L is a biomarker for mild TBI in amateur boxers and professional hockey players, that plasma tau is related to concussion severity, and that serum GFAP and UCH-L1 can detect mild to moderate TBI.
*Banyan UCH-L1™ and Banyan GFAP™ are registered trademarks of Banyan Biomarkers